Truist Raises Price Target on Treace Medical Concepts to $9 From $7, Maintains Hold Rating
Treace Medical Concepts Analyst Ratings
Morgan Stanley Raises Price Target on Treace Medical Concepts to $8 From $5.50, Keeps Equalweight Rating
Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), Treace Medical Concepts (TMCI) and Veeva Systems (VEEV)
UBS Downgrades Treace Medical, Cites Increasing Competition
Treace Medical Concepts Analyst Ratings
Treace Medical Concepts Analyst Ratings
Morgan Stanley Downgrades Treace Medical Concepts to Equal-Weight, Lowers Price Target to $5.5
UBS Adjusts Price Target on Treace Medical Concepts to $16 From $17, Maintains Buy Rating
UBS Maintains Buy on Treace Medical Concepts, Lowers Price Target to $16
Treace Medical Concepts Downgraded to Equal-weight Amid Competitive Pressures and Slower Growth Projections
Treace Medical Crashes as Guidance Cut Prompts J.P. Morgan Downgrade
Truist Securities Downgrades Treace Medical Concepts to Hold, Lowers Price Target to $7
JP Morgan Downgrades Treace Medical Concepts to Neutral, Lowers Price Target to $8
Truist Securities Downgrades Treace Medical Concepts to Hold From Buy, Lowers Price Target to $7 From $17
JPMorgan Downgrades Treace Medical Concepts to Neutral From Overweight, Cuts Price Target to $8 From $15
Stifel Downgrades Treace Medical Concepts to Hold From Buy, Cuts Price Target to $6 From $15
Treace Medical Concepts Analyst Ratings
Stifel Downgrades Treace Medical Concepts to Hold, Lowers Price Target to $6
Truist Financial Sticks to Their Buy Rating for Treace Medical Concepts (TMCI)